In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can form due to mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. such drug-combinations work in tyrosine kinase inhibitor-resistant sufferers with chronic myeloid leukemia continues to be to become elucidated. Launch Chronic myeloid leukemia (CML) is normally a stem cell disease seen as… Continue reading In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can